At Critical Outcome Technologies Inc., we are pioneering a better way to get safe and effective new drug therapies to people in a more timely, cost effective and efficient manner than the current pharmaceutical industry approach. Our business is focused on disease-specific drug discovery, optimization of the compounds for drug-like properties and pre-clinical development using a combination of rigorously developed and validated, proprietary computer simulations in collaboration with traditional medicinal chemistry expertise. Our approach allows for the discovery and development of potential new therapies faster and more efficiently.
CHEMSAS®: A new era in drug discovery
At the core of our business is our proprietary, artificial intelligence-based drug discovery platform called CHEMSAS® that rapidly accelerates drug discovery and lead optimization. CHEMSAS® is a process that utilizes a variety of available software tools and our own proprietary algorithms that are applied to complex 3D molecular structures to produce unique 2D data patterns composed of more than 250 descriptors. These unique 2D molecular data patterns are then used to develop predictive models relating molecular structure to specific target biological activities that previously required expensive and time consuming in vitro and in vivo laboratory tests.
CHEMSAS® uses a privileged fragment assembly approach to generate the initial series of drug candidates for profiling and optimization.
The CHEMSAS® process typically identifies six to ten novel, optimized small molecules on multiple scaffolds for each disease target that have a high probability of successful development.